Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance

摘要

Diagram showing patient treatment assignment, baseline epidermal growth factor receptor (EGFR) status, and sample availability. All patients had first-line epidermal growth factor receptor tyrosine kinase inhibitor resistance. EGFR mutation status assessed by plasma or tissue test: T790M+ detected, T790M− not detected, T790M? unknown